EXHIBIT 99.1


 FOR IMMEDIATE RELEASE:


              ABMC APPOINTS DONAL V. CARROLL TO BOARD OF DIRECTORS
                    New Director to Replace D. Joseph Gersuk

Kinderhook, N.Y., June 23, 2003 - American Bio Medica Corporation (NASDAQ: ABMC)
today announced the appointment of Donal V. Carroll to its board of directors.
Mr. Carroll is president and managing director of Redbrook Properties, a real
estate investment company with holdings in Europe and North America. Bringing
over 30 years of experience, Mr. Carroll's previous accomplishments include
founding and developing several successful finance and wholesale merchandising
companies. As an accomplished lawyer, Mr. Carroll also established a civil
rights defense practice which was the largest in Ireland for over a decade. He
will replace D. Joseph Gersuk, who resigned his position on the ABMC board on
June 19, 2003.

"We are pleased to welcome Donal Carroll to ABMC, and know that he brings with
him a wealth of entrepreneurial insights that will benefit our efforts," said
ABMC chairman and chief executive officer Gerald A. Moore. "At the same time, we
thank Joseph Gersuk for his contributions to the board, and wish him well in the
future."

About American Bio Medica Corporation
American Bio Medica Corporation is a biotechnology company that develops,
manufactures and markets accurate, cost-effective immunoassay diagnostic test
kits, including some of the world's most effective on-site drugs of abuse tests.
The company and its worldwide distribution network target the workplace,
government, corrections, clinical and educational markets. ABMC's Rapid Drug
Screen(R), Rapid One(R), Rapid Tec(R) and Rapid Tec Cup(TM) test for the
presence or absence of drugs of abuse in urine, while OralStat(R) tests for the
presence or absence of drugs of abuse in saliva. ABMC was recently named among
the 2002 Deloitte & Touche Technology Fast 500, a listing of the fastest-growing
technology companies in North America.

This release may contain forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results to
differ, and such differences could be material. Such risks and uncertainties
include, but are not limited to, the following: continued acceptance of the
Company's products, increased levels of competition in our industry, the
acceptance of new products, inherent risks associated with product development
and intellectual property rights, the Company's dependence on key personnel,
third party sales and suppliers. There can be no assurance that the Company will
be successful in addressing such risks and uncertainties. Investors are strongly
encouraged to review the section entitled "Risk Factors" in the Company's annual
report on Form 10-KSB for the fiscal year ended December 31, 2002, and quarterly
reports on Form 10-QSB on file with the Securities and Exchange Commission for a
discussion of risks and uncertainties that could affect operating results and
the market price of the Company's common shares.

                                      # # #



                                       5